Lisa Astor

Articles

Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score

June 3rd 2018

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.

Only Modest Benefit Seen With Taselisib in PIK3CA-Mutant Breast Cancer

June 2nd 2018

Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive, PIK3CA-mutant locally advanced or metastatic breast cancer

Symptom Tracking System Reduces Severity in Patients With Head and Neck Cancer

May 17th 2018

Patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.

Interest Builds in Targeting MET Mutations in Non-Small Cell Lung Cancer

February 28th 2018

Building on the success of molecularly targeted drugs aimed at relatively small subsets of patients, lung cancer researchers are increasingly aiming at the MET oncogene.

Checkpoint Blockade Therapy Clears Safety Hurdle for Patients With HIV and Cancer

January 26th 2018

Although there has been reluctance among oncology researchers to administer immunotherapy to patients with HIV who develop cancer, early signals from a small clinical trial suggest that such a strategy may be safe in certain settings.

CTC Assay Accurately Detects Precancerous Polyps

January 20th 2018

The CellMax biomimetic platform, a novel circulating tumor cell assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.

Oncolytic Virus Therapy Passes Early Efficacy Tests in Glioma Subtypes

January 7th 2018

A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme and anaplastic astrocytoma, in early clinical studies.

Positive CTC Findings Linked to High Recurrence Risk in HR+ Breast Cancer

December 9th 2017

Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer

Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma

November 12th 2017

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.